.jpeg)
{{ variable.name }}
Abxitinib is an oral small molecule Janus kinase (JAK) inhibitor that is an immunomodulatory drug.
1. Generic name: Abrocitinib (Abrocitinib)
2. Trade name: CI BINQO™
It is used to treat adults with refractory moderate to severe atopic dermatitis (eczema) and who are ineffective or inapplicable to other systemic drugs (including biological agents).
100 mg, tablets
1. Active ingredient:Abxitinib (50/100/200 mg/tablet).
2. Excipients include: Anhydrous calcium hydrogen phosphate, hypromellose, iron oxide red, etc.
1. Recommended dosage: 100 mg orally once a day. If the effect is insufficient after 12 weeks, it can be increased to 200 mg once a day.
2. Treatment of missed doses: If a dose is missed, take it within 12 hours; if it is skipped after 12 hours, take the next dose as originally planned.
3. Diet: Can be taken with food or on an empty stomach.
1. Renal insufficiency: moderate (eGFR30-59mL/min) reduced to 50 mg once a day, severe (eGFR<30mL/min) disabled.
2. CYP2C19 slow metabolizers: Reduce to 50 mg once a day.
3. Combined use of strong CYP2C19 inhibitors: Reduce to 50 mg once daily.
4. Hematological abnormalities: If platelets are <50,000/mm³ or neutrophils are <1,000/mm³, medication needs to be suspended.
1. Infection monitoring: Screening for tuberculosis and hepatitis B/C is required before treatment, and vigilance for opportunistic infections such as herpes zoster during treatment.
2. Vaccination: Avoid the use of live vaccines and complete recommended immunizations before treatment.
3. Laboratory monitoring: Blood routine, liver function, and blood lipids need to be monitored at baseline and after 4 weeks of treatment.
1. Pregnancy: Contraindicated. Effective contraception is required during treatment and 1 week after discontinuation of medication.
2. Lactation period: Breastfeeding is prohibited during treatment and 1 day after the last dose.
3. Elderly people (≥65 years old): No dose adjustment is required, but the risk of infection and thrombosis increases.
1. Common (≥1%) include: Nasopharyngitis (12.4%), nausea (14.5%), headache (7.8%), herpes simplex (4.2%), and thrombocytopenia (1.5%).
2. Serious adverse reactions include: Serious infection (2.3/100 person-years), thrombosis (0.3/100 person-years), and malignant tumors (0.5/100 person-years).
1. It is prohibited for those who are allergic to abuxitinib or its excipients.
2. It is prohibited to use antiplatelet drugs in combination with antiplatelet drugs (except low-dose aspirin ≤ 81 mg/day) 3 months before treatment.
1. Strong CYP2C19 inhibitors (such as fluvoxamine): The dose needs to be reduced to 50 mg once a day.
2. Strong CYP2C19/CYP2C9 inducers (such as rifampicin): Avoid combined use.
3. P-gp substrate (such as digoxin): The plasma concentration needs to be monitored.
1. Store in the original bottle to prevent moisture.
2. Store at room temperature (20-25℃), short-term storage at 15-30℃ is allowed.